Gynecologic Cancer:

G. J. Rustin, M. E. van der Burg on behalf of MRC and EORTC Collaborators

A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials)
J Clin Oncol (Meeting Abstracts) 2009 27: 1. [Abstract]  

F. Lecuru, A. Bats, P. Mathevet, D. Querleu, E. Leblanc, P. Morice, E. Darai, H. Marret, C. Collin, G. Chatellier, and F. Gilaizeau

Impact of sentinel lymph node biopsy on staging of early cervical cancer: Results of a prospective, multicenter study
J Clin Oncol (Meeting Abstracts) 2009 27: CRA5506. [Abstract]  

A. Dueñas-González, J. J. Zarba, J. C. Alcedo, P. Pattarunataporn, S. Beslija, F. Patel, L. Casanova, H. Barraclough, and M. Orlando

A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix
J Clin Oncol (Meeting Abstracts) 2009 27: CRA5507. [Abstract]  

S. Pignata, G. Scambia, A. Savarese, R. Sorio, E. Breda, G. Ferrandina, V. Gebbia, P. Musso, C. Gallo, and F. Perrone

Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): Activity and safety results of the MITO-2 randomized multicenter trial
J Clin Oncol (Meeting Abstracts) 2009 27: LBA5508. [Abstract]  

E. Pujade-Lauraine, S. Mahner, J. Kaern, V. Gebski, M. Heywood, P. Vasey, A. Reinthaller, I. Vergote, S. Pignata, and A. Ferrero

A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG)
J Clin Oncol (Meeting Abstracts) 2009 27: LBA5509. [Abstract]  

J. Herrstedt, J. Huober, F. Priou, H. Müller, M. Baekelandt, C. Kurzeder, J. Pfisterer, A. Stähle, I. Ray-Coquard, and A. du Bois

A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): Gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): Survival of FIGO stage I-IIA patients
J Clin Oncol (Meeting Abstracts) 2009 27: LBA5510. [Abstract]  

Developmental Therapeutics: Immunotherapy:

S. J. Schuster, S. S. Neelapu, B. L. Gause, F. M. Muggia, J. P. Gockerman, E. M. Sotomayor, J. N. Winter, C. R. Flowers, A. M. Stergiou, L. W. Kwak for the BiovaxID Phase III Study Investigators

Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results
J Clin Oncol (Meeting Abstracts) 2009 27: 2. [Abstract]  

Breast Cancer:

J. O'Shaughnessy, C. Osborne, J. Pippen, M. Yoffe, D. Patt, G. Monaghan, C. Rocha, V. Ossovskaya, B. Sherman, and C. Bradley

Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial
J Clin Oncol (Meeting Abstracts) 2009 27: 3. [Abstract]  

A. Tutt, M. Robson, J. E. Garber, S. Domchek, M. W. Audeh, J. N. Weitzel, M. Friedlander, and J. Carmichael

Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: CRA501. [Abstract]  

V. C. Tjan-Heijnen, M. J. Pepels, M. de Boer, G. F. Borm, J. A. van Dijck, C. H. van Deurzen, E. M. Adang, M. B. Menke-Pluymers, P. J. van Diest, and P. Bult

Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0[i+]) in the sentinel lymph node (SN): Results from the MIRROR study
J Clin Oncol (Meeting Abstracts) 2009 27: CRA506. [Abstract]  

R. E. Aubert, E. J. Stanek, J. Yao, J. R. Teagarden, M. Subar, R. S. Epstein, T. C. Skaar, Z. Desta, and D. A. Flockhart

Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors
J Clin Oncol (Meeting Abstracts) 2009 27: CRA508. [Abstract]  

V. Dezentje, N. J. Van Blijderveen, H. Gelderblom, H. Putter, M. P. Van Herk-Sukel, M. K. Casparie, A. C. Egberts, J. W. Nortier, and H. J. Guchelaar

Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiologic study
J Clin Oncol (Meeting Abstracts) 2009 27: CRA509. [Abstract]  

L. J. Esserman, C. Perou, M. Cheang, A. DeMichele, L. Carey, L. J. van 't Veer, J. Gray, E. Petricoin, K. Conway, N. Hylton, D. Berry I-SPY Investigators

Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657)
J Clin Oncol (Meeting Abstracts) 2009 27: LBA515. [Abstract]  

A. Valachis, D. Mauri, N. P. Polyzos, D. Mavroudis, V. Georgoulias, and G. Casazza

Partial breast irradiation or whole breast radiotherapy for early breast cancer: A meta-analysis of randomized controlled trials
J Clin Oncol (Meeting Abstracts) 2009 27: CRA532. [Abstract]  

Gastrointestinal (Colorectal) Cancer:

N. Wolmark, G. Yothers, M. J. O'Connell, S. Sharif, J. N. Atkins, T. E. Seay, L. Feherenbacher, S. O'Reilly, and C. J. Allegra

A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08
J Clin Oncol (Meeting Abstracts) 2009 27: LBA4. [Abstract]  

J. Gerard, D. Azria, S. Gourgou-Bourgade, I. Martel-Laffay, C. Hennequin, P. Etienne, V. Vendrely, T. Conroy, E. Francois, and C. Montoto-Grillot

Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2
J Clin Oncol (Meeting Abstracts) 2009 27: LBA4007. [Abstract]  

C. Aschele, C. Pinto, S. Cordio, G. Rosati, A. Tagliagambe, S. Artale, P. Rosetti, S. Lonardi, L. Boni, L. Cionini, and on behalf of STAR Network Investigators

Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial
J Clin Oncol (Meeting Abstracts) 2009 27: CRA4008. [Abstract]  

R. James, S. Wan, R. Glynne-Jones, D. Sebag-Montefiore, L. Kadalayil, J. Northover, D. Cunningham, H. Meadows, J. Ledermann, and National Cancer Research Institute (NCRI) ACT II Trial Management Group

A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II)
J Clin Oncol (Meeting Abstracts) 2009 27: LBA4009. [Abstract]  

E. P. Mitchell, M. Lacouture, H. Shearer, N. Iannotti, B. Piperdi, M. Pillai, F. Xu, and M. Yassine

Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC)
J Clin Oncol (Meeting Abstracts) 2009 27: CRA4027. [Abstract]  

G. A. Poultsides, E. L. Servais, L. B. Saltz, S. Patil, N. E. Kemeny, J. G. Guillem, M. Weiser, L. K. Temple, W. Wong, and P. B. Paty

Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment
J Clin Oncol (Meeting Abstracts) 2009 27: CRA4030. [Abstract]  

Cancer Prevention:

R. T. Chlebowski, A. Schwartz, H. Wakelee, G. L. Anderson, M. L. Stefanick, J. E. Manson, J. W. Chien, C. Chen, J. Wactawski-Wende, M. Gass for the Women's Health Initiative Investigators

Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial
J Clin Oncol (Meeting Abstracts) 2009 27: CRA1500. [Abstract]  

J. M. Croswell, S. G. Baker, P. M. Marcus, J. D. Clapp, and B. S. Kramer

Cumulative risk for a false-positive test using low-dose computed tomography in lung cancer screening
J Clin Oncol (Meeting Abstracts) 2009 27: CRA1502. [Abstract]  

Gastrointestinal (Noncolorectal) Cancer:

J. Neoptolemos, M. Büchler, D. D. Stocken, P. Ghaneh, D. Smith, C. Bassi, M. Moore, D. Cunningham, C. Dervenis, and D. Goldstein

ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: LBA4505. [Abstract]  

H. Riess, U. Pelzer, G. Deutschinoff, B. Opitz, M. Stauch, P. Reitzig, S. Hahnfeld, A. Hilbig, J. Stieler, and H. Oettle

A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial
J Clin Oncol (Meeting Abstracts) 2009 27: LBA4506. [Abstract]  

E. Van Cutsem, Y. Kang, H. Chung, L. Shen, A. Sawaki, F. Lordick, J. Hill, M. Lehle, A. Feyereislova, and Y. Bang

Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)
J Clin Oncol (Meeting Abstracts) 2009 27: LBA4509. [Abstract]  

Genitourinary Cancer:

B. I. Rini, S. Halabi, J. Rosenberg, W. M. Stadler, D. A. Vaena, J. N. Atkins, J. Picus, P. Czaykowski, J. Dutcher, and E. J. Small

Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206
J Clin Oncol (Meeting Abstracts) 2009 27: LBA5019. [Abstract]  

Head and Neck Cancer:

C. Nutting, R. A'Hern, M. S. Rogers, M. A. Sydenham, F. Adab, K. Harrington, S. Jefferies, C. Scrase, B. K. Yap, E. Hall, and on behalf of the PARSPORT Trial Management Group

First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005)
J Clin Oncol (Meeting Abstracts) 2009 27: LBA6006. [Abstract]  

Health Services Research:

P. C. Nathan, K. K. Ness, M. M. Hudson, M. Mahoney, J. S. Ford, W. Landier, G. Armstrong, T. Henderson, L. L. Robison, and K. C. Oeffinger

Cancer screening in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS)
J Clin Oncol (Meeting Abstracts) 2009 27: CRA6501. [Abstract]  

S. Cheng, M. Dietrich, S. Finnigan, A. Sandler, J. Crites, L. Ferranti, A. Wu, and D. Dilts

A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies
J Clin Oncol (Meeting Abstracts) 2009 27: CRA6509. [Abstract]  

Lung Cancer:

P. Fouret, D. Planchard, J. Mendiboure, N. S. Kamal, K. A. Olaussen, P. Bertrand, R. Pirker, A. Dunant, T. Le Chevalier, J. C. Soria IALT-Bio Investigators

MSH2 and adjuvant cisplatin-based chemotherapy in non-small cell lung cancer
J Clin Oncol (Meeting Abstracts) 2009 27: CRA7502. [Abstract]  

C. P. Belani, T. Brodowicz, T. Ciuleanu, J. H. Kim, M. Krzakowski, E. Laack, Y. L. Wu, P. Peterson, K. Krejcy, and C. Zielinski

Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)
J Clin Oncol (Meeting Abstracts) 2009 27: CRA8000. [Abstract]  

V. A. Miller, P. O'Connor, C. Soh, F. Kabbinavar for the ATLAS Investigators

A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
J Clin Oncol (Meeting Abstracts) 2009 27: LBA8002. [Abstract]  

R. S. Herbst, Y. Sun, S. Korfee, P. Germonpré, N. Saijo, C. Zhou, J. Wang, P. Langmuir, S. J. Kennedy, and B. E. Johnson

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
J Clin Oncol (Meeting Abstracts) 2009 27: CRA8003. [Abstract]  

Melanoma:

D. J. Schwartzentruber, D. Lawson, J. Richards, R. M. Conry, D. Miller, J. Triesman, F. Gailani, L. B. Riley, D. Vena, and P. Hwu

A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma
J Clin Oncol (Meeting Abstracts) 2009 27: CRA9011. [Abstract]  

A. Hauschild, A. M. Eggermont, E. Jacobson, and S. J. O'Day

Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM)
J Clin Oncol (Meeting Abstracts) 2009 27: LBA9012. [Abstract]  

M. A. Henderson, B. Burmeister, J. F. Thompson, J. Di Iulio, R. Fisher, A. Hong, R. Scolyer, K. Shannon, H. Hoesktra, and J. Ainslie

Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01)
J Clin Oncol (Meeting Abstracts) 2009 27: LBA9084. [Abstract]  

Patient Care:

G. Quinn, S. T. Vadaparampil, P. Jacobsen, J. Lee, J. Lancaster, G. Bepler, D. L. Keefe, and T. L. Albrecht

National survey of physicians practice patterns: Fertility preservation and cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: CRA9508. [Abstract]  

Pediatric Cancer:

M. Stuber, K. Meeske, B. Zebrack, K. Krull, K. Stratton, W. Leisenring, L. Robison, and L. Zeltzer

Prevalence and predictors of posttraumatic stress disorder in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study
J Clin Oncol (Meeting Abstracts) 2009 27: CRA10002. [Abstract]  

To see an article, click its [Full Text] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.